how to maximize clinical benefits for patients with alk-positive non-small cell lung cancer
Published 7 years ago • 293 plays • Length 3:53Download video MP4
Download video MP3
Similar videos
-
2:00
updated data from phase 2 study of alectinib in alk–positive non–small–cell lung cancer
-
1:01
targeting alk rearrangements in non-small cell lung cancer
-
0:58
progress in the treatment of alk-positive non-small cell lung cancer
-
3:34
alk-positive nsclc: the role of treatment selection and sequencing
-
1:02
blood tests for identifying and monitoring alk-positive non-small cell lung cancer
-
1:40
maximizing treatment benefits in nsclc
-
0:38
addressing treatment strategies for limited stage small cell lung cancer
-
1:24
personalized cancer treatment with er inhibition strategies for nsclc
-
0:56
nautika1: safety and tolerability of neoadjuvant alectinib in alk-positive nsclc
-
0:58
no clear evidence for benefit with addition of rova-t to chemo for extensive sclc
-
2:10
molecularly-guided treatment of advanced nsclc: alk inhibitor sequencing
-
2:34
cns metastasis in alk positive lung cancer
-
5:59
targeted therapy in consolidation setting for lung cancer
-
2:07
clinical updates on alk inhibitor treatment strategies for nsclc
-
2:37
crown: lorlatinib in treatment-naïve patients with alk-positive advanced nsclc
-
0:51
uk excels at molecular testing for lung cancer
-
3:46
ifct-1803 lorlatu cohort: real-world evidence supporting lorlatinib in alk nsclc
-
11:14
holistic management of patients with alk-positive nsclc
-
2:35
brain metastases in alk nsclc